Core Insights - Alpha Modus Holdings, Inc. emphasizes a disciplined approach to capital management and strategic execution since going public, focusing on long-term value creation rather than short-term gains [3][4][6] Group 1: De-SPAC Process - Alpha Modus chose to avoid survival capital during its de-SPAC process, opting instead for funding primarily through the CEO's family to maintain cap-table integrity and strategic optionality [4][5][6] - This approach reflects management's belief that capital discipline is a strategic asset, allowing the company to emerge from the de-SPAC process with a strong balance sheet and decision-making authority [6] Group 2: Strategic Focus Post-Listing - The company prioritized building durable leverage across three foundational pillars rather than focusing on immediate revenue, believing that establishing leverage before scaling would lead to more sustainable growth [7] Group 3: Intellectual Property Strategy - Alpha Modus's intellectual property (IP) is consumer-centric, focusing on the interaction between consumers and their physical environment, which differentiates it from competitors that focus on backend technologies [8][12] - The company has filed 23 IP enforcement actions since going public, with five favorably resolved, demonstrating its commitment to protecting its consumer-facing IP [15][26] Group 4: Alpha Cash Initiative - Alpha Cash serves as a physical distribution layer for consumer engagement and monetization, transitioning from concept to pilot execution with national retail partners [17][18] - The initiative is designed to enhance consumer interaction in both physical and digital environments, positioning Alpha Modus for long-term growth [18] Group 5: Capital Strategy - Alpha Modus maintains a strong capital strategy that emphasizes optionality over urgency, allowing the company to avoid toxic financing structures and ensuring uninterrupted operations [19][21] - The recent filing of a $250 million S-3 registration statement is intended to enhance long-term capital flexibility and support strategic growth initiatives [22] Group 6: Achievements Since Going Public - Since becoming public, Alpha Modus has navigated the de-SPAC process, preserved capital flexibility, built a defensible consumer-centric IP portfolio, and established enterprise-grade deployment readiness [26] Group 7: Market Positioning - The company believes that the true value in AI-enabled physical retail lies at the consumer interface, positioning itself as a linchpin in the ecosystem by owning the consumer-facing layer that connects various technologies [23][27]

Core Insights - BitFuFu Inc. reported an increase in Bitcoin production and operational metrics for January 2026, highlighting growth in managed hashrate and power capacity while maintaining fleet efficiency [2][4]. Bitcoin Holdings and Production - As of January 31, 2026, BitFuFu holds 1,796 BTC, an increase of 16 BTC from December 2025 [6]. - The company produced 229 BTC in January 2026, a month-over-month increase of 41 BTC, with 183 BTC from cloud mining and 46 BTC from self-mining [7][4]. Hashrate Overview - Total hashrate under management reached 29.6 EH/s, reflecting a year-over-year increase of 46.5% and a month-over-month increase of 13.4% [12]. - Power capacity under management is 520 MW, which represents a year-over-year increase of 22.6% and a month-over-month increase of 8.8% [8][12]. - Average fleet efficiency improved to 17.5 J/TH, a decrease of 0.8 J/TH from the previous month [12]. Upcoming Events - BitFuFu will participate in the 38th Annual ROTH Conference from March 22-24, 2026, in Dana Point, CA [9].

Core Insights - Edible Garden AG Incorporated will participate in ECRM's Total Wellness: GLP-1, Weight Management, Nutrition & Vitamin Session from February 10–12, 2026, in Chicago, Illinois, to enhance retail partnerships and showcase its product offerings [1][2]. Company Overview - Edible Garden is a leader in controlled environment agriculture (CEA), providing sustainable, locally grown organic produce through a Zero-Waste Inspired farming model, available in over 5,000 retail locations across the U.S., Caribbean, and South America [5]. - The company operates advanced vertically integrated greenhouses and processing facilities, including locations in Grand Rapids, Michigan, Webster City, Iowa, and Belvidere, New Jersey [5]. Product Offerings - At the ECRM event, Edible Garden will showcase its Kick Sports Nutrition line, clean labeled sports nutrition products, weight management solutions, and protein powders under the Vitamin Way® and Vitamin Whey® brands [3][4]. - The company is focused on meeting the growing consumer interest in GLP-1 support, weight management, and clean nutrition, aiming to build a portfolio that caters to wellness-focused consumers [4]. Technology and Innovation - Edible Garden utilizes proprietary GreenThumb 2.0 software to optimize growing conditions and reduce food miles, along with patented Self-Watering displays to enhance plant shelf life [6]. - The company holds multiple patents in advanced aquaculture technologies, including a closed-loop shrimp farming system and a modular recirculating aquaculture setup [6]. Industry Recognition - Edible Garden has been recognized as a FoodTech 500 firm and is a member of Walmart's Project Gigaton sustainability initiative, highlighting its commitment to sustainability and innovation in the food technology sector [7].

Core Viewpoint - FLSmidth & Co. A/S announces preliminary and unaudited financial results for the full year 2025, exceeding previous expectations, and introduces financial guidance for 2026 focusing on organic revenue growth and Adjusted EBITA margin [1][5]. Financial Results for FY 2025 - Preliminary financial figures for FY 2025 show consolidated revenue of DKK 14.6 billion, with an Adjusted EBITA margin of 15.9%, surpassing the previous guidance of 15.0% to 15.5% [5]. - Order intake for FY 2025 reached DKK 15.0 billion, with organic revenue growth at -1% [2]. - The company recognized an impairment of deferred tax assets in Denmark amounting to approximately DKK 600 million in Q4 2025 [2]. Financial Guidance for FY 2026 - FLSmidth expects organic revenue growth to range from -1% to 4% for FY 2026, with an Adjusted EBITA margin projected between 15.5% and 16.5% [7][6]. - The guidance reflects expectations of stable market conditions and customer investment levels in the mining industry, with no significant regulatory changes anticipated [8]. Business Segment Performance - The Service business is expected to achieve organic revenue growth of 2% to 5%, driven by demand for productivity-enhancing solutions [10]. - The Products business anticipates a decline in organic revenue growth of -15% to -5% due to a reduced order backlog and low investment activity [10]. - The Pumps, Cyclones & Valves (PC&V) segment is projected to grow organically by 4% to 7%, supported by robust market conditions [10]. Upcoming Reports - The full annual report for 2025 is scheduled for publication on 18 February 2026 [9].

Core Insights - IMUNON, Inc. is undergoing a strategic reorganization to eliminate non-essential headcount and redefine job roles to reduce operating expenses while advancing its Phase 3 clinical trial for IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer [1][2] - Dr. Khursheed Anwer, the Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years, marking a transition period for the company as it focuses on the commercial potential of DNA-mediated immunotherapy [1][2][3] Company Developments - The Phase 3 OVATION 3 study is progressing ahead of schedule, with enrollment exceeding projections and plans to activate additional clinical sites [1][5] - The OVATION 2 study demonstrated a median 13-month increase in overall survival when IMNN-001 was combined with standard chemotherapy, leading to significant interest in presenting the data at major oncology meetings [2][4] - IMUNON's proprietary TheraPlas platform technology is central to the development of IMNN-001, which is designed to enhance immune response against cancer [6][9] Clinical Trial Insights - The OVATION 3 trial is designed with at least 95% statistical power for its primary endpoint of overall survival, including two planned interim analyses to expedite FDA submission if results are favorable [5] - IMNN-001 has shown promising results in previous trials, including a Phase 1b study, and is currently being evaluated in the context of advanced ovarian cancer treatment [6][9] Market Context - Epithelial ovarian cancer remains a significant health challenge, with approximately 20,000 new cases annually in the U.S., and a high percentage diagnosed at advanced stages [7] - The need for effective therapies is underscored by poor five-year survival rates for advanced-stage patients, highlighting the potential impact of IMUNON's innovative treatments [7]

Company Overview - Alumis Inc. is a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases [2] - The company utilizes a proprietary data analytics platform and precision approach to enhance patient health and outcomes [2] Product Pipeline - Alumis is developing a pipeline of oral tyrosine kinase 2 inhibitors, including envudeucitinib (formerly ESK-001), aimed at treating systemic immune-mediated disorders such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus [2] - The pipeline also features A-005 for neuroinflammatory and neurodegenerative diseases, and lonigutamab, a subcutaneously delivered therapy for thyroid eye disease [2] - Several preclinical programs have been identified through the company's precision approach [2] Investor Engagement - Alumis will participate in multiple investor conferences, including the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026, and the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026 [4] - Live webcasts of these events will be accessible on the company's website, with replays archived for 90 days [1][4]

PITTSBURGH, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Duolingo, Inc. (Nasdaq: DUOL), the world's leading mobile learning platform, will announce its results for the fourth quarter and full year ending December 31, 2025, following the close of the U.S. market on Thursday, February 26, 2026. The Company will host a video webcast at 5:30 p.m. ET on that day. The live video webcast will be accessible to the public through Duolingo’s Investor Relations website at https://investors.duolingo.com. A replay of the event wil ...

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter period ended December 31, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will ho ...

THORNTON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ascent Solar Technologies (“Ascent” or the “Company”) (Nasdaq: ASTI), today announced its plans to continue development of distributed power receiving products in 2026 to account for growing demand for space-based energy beaming technologies. These development efforts include both internally funded research and development as well as continued Collaborative Agreement Notice program work with the NASA Marshall Spaceflight Center and Glenn Research Center, wh ...

RA'ANANA, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has entered into a definitive agreement with a single healthcare-focused, institutional investor for a registered direct offering priced at-the-market under Nasdaq Rules of an aggregate of 6,785,715 ordinary shares (or ordinary share equivalents in lieu t ...